Overview

Adriamycin was a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma. Adriamycin was often combined with other drugs in specific chemotherapy regimens. Adriamycin was also known by its drug name, doxorubicin,

Adriamycin was an anticancer drug used in chemotherapy. It was a member of a drug class called anthracycline antibiotics. Adriamycin was also a topoisomerase inhibitor. Adriamycin was believed to work by damaging DNA and blocking cell division in several ways.

How was it taken?

Adriamycin was usually administered as an intravenous infusion during chemotherapy treatment.

Side effects

The FDA-approved label for Adriamycin listed common side effects including hair loss, nausea, and vomiting.

Rare but serious side effects listed for Adriamycin included radiation-induced toxicity and fetal harm. 

For more details about this treatment, visit:

Adriamycin PFS — RxList